Tier B

NADH (Reduced Nicotinamide Adenine Dinucleotide)

Also known as: Reduced NAD · ENADA (stabilized NADH) · Coenzyme 1

1 PMID anchor · MITO · CNS · IMMUNE · Last reviewed 2026-06-08

Read full dossier → Deep-dive article → JSON (nadh.json)

Mechanism of action

Mitochondrial Complex I electron donor
Tetrahydrobiopterin recycling
Dopamine biosynthesis support
Cellular ATP production

Molecular + tissue targets

Mitochondrial electron transport chain
Dopamine biosynthesis pathway
Cellular bioenergetics

Dosage range

5-20 mg/day (Forsyth 1999 PMID 10071523 CFS RCT 10 mg/day · Birkmayer 2002 jet-lag 5 mg)

Safety notes

Generally well tolerated; long-term human safety beyond 6 months limited; NADH formulation stability requires enteric coating

Cross-market regulatory status

🇺🇸 FDA

DSHEA dietary supplement (since 1996)

🇪🇺 EFSA

Novel Food classification (case-by-case)

🇧🇷 ANVISA

RDC 243/2018 dietary supplement framework

Evidence anchors (PubMed) · 1

PMID 10071523 RCT positive outcome

Forsyth LM et al. (1999) Ann Allergy Asthma Immunol

Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome

Canonical ENADA stabilized NADH 10 mg/d crossover double-blind placebo-controlled RCT · n=26 CFS patients · 8/26 (31%) responded favorably to NADH vs 2/26 (8%) placebo · verified 2026-06-07 · NOT PMID 10367612 (different paper Ambulatory blood pressure responses Psychosom Med 1999)

Common use cases

chronic fatigue syndrome (research context)
jet-lag cognition
cellular energy support

Cross-reference

Health goals: longevity stack cognitive support athletic performance heart health

Lifestyles: senior 60 plus high stress athletic performance

Full dossier: /ingredients/nadh/

Machine-readable JSON: /api/nc/nadh.json